Phase IV

August 19, 2019

ESC preview – Medicines Company hopes for a starring role

Novartis has been reduced to a Paragon data dredge, but results with The Medicines Company’s inclisiran, Astrazeneca’s Brilinta and Cellaegis’ AutoRIC device should pique interest.

ESC preview – Medicines Company hopes for a starring role

Boston Scientific’s plan to keep the rhythm going

Ablation groups scramble to cope with Cabana

GeneSight trial miss leaves Myriad depressed

Vifor takes iron therapy expansion to heart

Smith & Nephew innovates in wound care, but no trade sale in sight

TCT 2016: Early clinical data back Medtronic’s inside-out stent

Interview – Xhale helps pharma breathe easy on compliance

Glaxo shoots itself in the foot... again

Cardiovascular radiance for Jardiance

Januvia's surprising all clear, courtesy of Tecos

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Esmo 2019 preview – Parps on parade

Alzheimer's setbacks have prompted $39bn of market cap losses this year

Should the diabetes development road end for Sanofi?

Six burning Otezla questions

The PCSK9 wars continue, but at what cost?